EUVIMEDEUVIMED entdecken
Open Access

Timing matters: Impact of covalent BTK inhibitor dose modifications on outcomes in chronic lymphocytic leukemia/small lymphocytic leukemia—A 7‐year real‐world study

Jiaojiao Zhang iD, Jing Luo, Xiaozhong Shen, Jiayi Ren, Weiyang Liu, Li Chen, Lu Jiang, Xiangqin Weng, Jin Wang, Jian-Qing Mi

Cancer · 2026

DOI: 10.1002/cncr.70578 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer, 2026. Verfasst von Jiaojiao Zhang und 9 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, National Research Center for Translational Medicine at Shanghai, Ruijin H…. Hauptthemen laut MEDLINE: Leukemia, Lymphocytic, Chronic, B-Cell, Agammaglobulinaemia Tyrosine Kinase, Protein Kinase Inhibitors. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Shanghai Hematology Clinical Specialty Capacity Enhancement Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Covalent BTK inhibitors (cBTKis) are the cornerstone of chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia (SLL) therapy, yet real‐world data on dose modifications and their differential impact on long‐term outcomes remain incompletely defined. This study investigated the incidence, timing, and the effectiveness of drug switching in a real‐world CLL cohort.

Methods

In this 7‐year retrospective real‐world study, 324 CLL/SLL patients treated at a specialized Shanghai outpatient clinic (April 2018–April 2025; median follow‐up, 42 months) were analyzed. Dose modifications were classified as dose interruption (DI) or dose reduction (DR). Their prognostic impact on progression‐free (PFS) and overall survival (OS) was assessed by Kaplan–Meier analysis and multivariate Cox regression.

Results

The 42‐month PFS rate was 70.2%. Of 324 patients, 229 (70.7%) experienced dose reductions or interruptions; infections were the predominant cause (61.9%). The full‐dose (FD) group ( n = 90) demonstrated superior 4‐year PFS (93% vs. 58%, p < .001) and OS (98% vs. 76%, p = .007). Early modifications (0–3 months) were independent predictors of inferior PFS (hazard ratio [HR], 3.93, p = .008) and OS (HR, 3.29, p = .014). Prolonged DI (>14 days) was associated with inferior PFS (HR, 2.64) and OS (HR, 2.15), whereas DR and short DI (≤14 days) had negligible impact. Early (0–3 months) prolonged DI was devastating (3‐year PFS, 41.2%; HR, 3.84, p < .001). cBTKi switching ( n = 82; 100% nonprogression‐driven) shortened DI (median, 6 vs. 14 days) and was independently associated with superior OS (HR, 0.34, p = .018) and PFS (HR, 0.36, p = .022).

Conclusions

Early prolonged DI is the dominant adverse prognostic factor in cBTKi‐treated CLL/SLL. Proactive switching minimizes treatment gaps and improves survival, supporting a timing‐aware, DI‐ versus DR‐informed approach to dose management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Lymphocytic, Chronic, B-CellAgammaglobulinaemia Tyrosine KinaseProtein Kinase InhibitorsHumansFemaleAgedRetrospective StudiesMaleMiddle AgedPrognosisAged, 80 and overTime FactorsDose-Response Relationship, DrugProgression-Free SurvivalTreatment OutcomeDrug Tapering

Stichwörter der Autor:innen

BTKi switchingchronic lymphocytic leukemiacovalent BTK inhibitordose interruptiondose reductionreal‐world study

Substanzen

Agammaglobulinaemia Tyrosine KinaseProtein Kinase InhibitorsBTK protein, human

Autor:innen und Institutionen

  • State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, C…
  • Shanghai Key Laboratory of Gene Editing and Cell-based Immunotherapy for Hematological Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

ORCID-Profile: Jiaojiao Zhang

Förderung

  • Shanghai Hematology Clinical Specialty Capacity Enhancement Project

Zitieren

APA

Zhang, J., Luo, J., Shen, X., Ren, J., Liu, W., Chen, L., Jiang, L., Weng, X., Wang, J., & Mi, J. Q. (2026). Timing matters: Impact of covalent BTK inhibitor dose modifications on outcomes in chronic lymphocytic leukemia/small lymphocytic leukemia—A 7‐year real‐world study. Cancer. https://doi.org/10.1002/cncr.70578

Vancouver

Zhang J, Luo J, Shen X, Ren J, Liu W, Chen L, et al. Timing matters: Impact of covalent BTK inhibitor dose modifications on outcomes in chronic lymphocytic leukemia/small lymphocytic leukemia—A 7‐year real‐world study. Cancer. 2026. doi:10.1002/cncr.70578

BibTeX
@article{Zhang2026,
  author = {Zhang, Jiaojiao and Luo, Jing and Shen, Xiaozhong and Ren, Jiayi and Liu, Weiyang and Chen, Li and Jiang, Lu and Weng, Xiangqin and Wang, Jin and Mi, Jian-Qing},
  title = {Timing matters: Impact of covalent BTK inhibitor dose modifications on outcomes in chronic lymphocytic leukemia/small lymphocytic leukemia—A 7‐year real‐world study},
  journal = {Cancer},
  year = {2026},
  doi = {10.1002/cncr.70578}
}
Kostenlos starten →